- Sirona Biochem (SBM) has signed a research agreement with the International Centre for Genetic Engineering and Biotechnology (ICGEB)
- ICGEB scientists will test Sirona antivirals against SARS-CoV-2 (COVID-19) with the goal of creating new treatment options
- Results from the initial evaluation are expected in approximately 12 weeks
- Sirona Biochem is a cosmetic ingredient and drug discovery company
- Sirona Biochem (SBM) is unchanged, trading at $0.12 per share
Sirona Biochem (SBM) has signed a research agreement with the ICGEB.
Established in 1983, the ICGEB is a leading not-for-profit IGO for research, training and technology in biotech and the life sciences. It counts almost 70 member states.
The parties intend to advance Sirona’s library of antiviral compounds – which are produced at its TFChem subsidiary – at the ICGEB’s Laboratory of Molecular Virology in Trieste, Italy.
ICGEB scientists will begin by testing the antivirals against SARS-CoV-2 (COVID-19) with the goal of creating new treatment options.
Results from the initial evaluation are expected in approximately 12 weeks.
The collaboration may be expanded to other viruses upon positive results.
Sirona Biochem is a cosmetic ingredient and drug discovery company specializing in stabilizing carbohydrate molecules to improve efficacy and safety. Its compounds are licensed to leading companies around the world.
Sirona Biochem (SBM) is unchanged, trading at $0.12 per share as of 11:57 am ET.
